November 2011 Newsletter

November 22, 2011:

Orlando AAO Highlights Laser Cataract Surgery & Retina Pharmaceuticals

AAO Meeting Focuses on LRCS and Retina Meeting spotlights a wealth of topics:

IOLs
Laser Refractive Cataract Surgery
Anti-VEGFs
Sustained-Release Steroids
Anti-Infectives for Prophylaxis
Other Pipeline Agents & Technologies
Micropulse Laser
Advances in Vitreoretinal Surgery
Excimer Lasers
Cornea
Diagnostic Instruments

November 22, 2011:

FDA Approves Regeneron’s Eylea for US Market

This anti-VEGF fusion protein will enter the US marketplace this week, joining Roche/Genentech’s Lucentis and off-label Avastin.

November 22, 2011:

FDA Effectively Denies Approval for Alimera’s Iluvien

The FDA has determined that questions regarding safety and effectiveness have precluded regulatory approval of Alimera Science’s Iluvien, an investigational sustained-release fluocinolone acetonide insert for diabetic macular edema.

November 22, 2011:

Two Promising RP Technologies from Germany

Retina Implant AG ’s subretinal device for people blinded by retinitis pigmentosa is an ambitious retinal prosthesis that requires no external equipment and has a chip with 1,500 electrodes.

November 22, 2011:

Innovation Summit Explores FDA Process & the Impact of the Recession on Venture Funding

More than 600 attendees, who were mainly executives from large ophthalmic companies, start-ups, and venture capital companies, came together the day before the start of the AAO to consider the future of ophthalmic innovation.

November 22, 2011:

Minimally Invasive Glaucoma Surgery Devices To Drive Future Surgical Device Growth in Glaucoma Market

Minimally-invasive surgical technologies are set to boost the glaucoma device market.

November 22, 2011:

November 2011 News Briefs

This month's news includes the latest from Staar Surgical, Iridex, Alcon, Synergetics and Bausch & Lomb.

Social media